Biomet still gaining from trauma buy in Q4
This article was originally published in Clinica
Biomet once again benefited from its purchase of Johnson & Johnson’s DePuy trauma business during its fourth fiscal quarter. Overall, sales grew 6% to $783.9m, but many of its franchises shrank (see table below). These losses were offset by 62% growth in Biomet’s sports, extremities and trauma unit, to $159.2m.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.